New Frontier Group
Vision Fund joins $300m round for China vaccine developer
SoftBank Vision Fund 2 and 5Y Capital have led a $300 million Series C extension for Suzhou Abogen Biosciences, a Chinese vaccine developer focused on mRNA products, including one for COVID-19.
New Frontier to privatize US-listed China hospital business
The New Frontier Group-led consortium that acquired Chinese hospital operator United Family Healthcare (UFH) through a special purpose acquisition company (SPAC) in 2019 is now looking to take the US-listed business private at a valuation of around $1.6...
Alternative fund structures: Alternate universe
Irregular fund structures, including single-asset platforms, are often the most appropriate inroad for investors in developing Asia. But it has taken a pandemic to bring them to the fore
New Frontier Group: Another kind of platform
Led by two former executives with The Blackstone Group in Asia, New Frontier Group has so far looked beyond traditional PE funding channels as it builds large-scale Chinese healthcare platforms